ASTX-029

DB18900InvestigationalSmall molecule

ASTX-029 is under investigation in clinical trial NCT03520075 (Study of ASTX029 in Subjects With Advanced Solid Tumors).

Mechanism: Pharmacologically active on Extracellular signal-regulated kinase (ERK)
Curator reviewed
Formula / weight: C₂₉H₃₁ClFN₅O₅ · 584.05 g/mol (avg)
Also known as: 2H-ISOINDOLE-2-ACETAMIDE, 6-(5-CHLORO-2-((TETRAHYDRO-2H-PYRAN-4-YL)AMINO)-4-PYRIMIDINYL)-N-((1S)-1-(3-FLUORO-5-METHOXYPHENYL)-2-HYDROXYETHYL)-1,3-DIHYDRO-.ALPHA.-METHYL-1-OXO-, (.ALPHA.R)-
Code names: ASTX-029

Resolves to

Compound

Structure

InChIKeyBVRGQPJKSKKGIH-PUAOIOHZSA-NSMILESCOC1=CC(F)=CC(=C1)[C@@H](CO)NC(=O)[C@@H](C)N1CC2=CC=C(C=C2C1=O)C1=NC(NC2CCOCC2)=NC=C1Cl

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of ASTX-029, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.